In Alzheimer's disease (AD) basic research and drug discovery, mouse models are essential
resources for uncovering biological mechanisms, validating molecular targets and screening …

To date, there is no reliable biomarker for the assessment or determination of cognitive
dysfunction in Alzheimer's disease and related dementia. Such a biomarker would not only …

Background Regenerative therapies to mitigate Alzheimer's disease (AD) neuropathology
have shown very limited success. In the recent era, extracellular vesicles (EVs) derived from …

Dendritic spine loss is recognized as an early feature of Alzheimer's disease (AD), but the
underlying mechanisms are poorly understood. Dendritic spine structure is defined by …

Alzheimer's disease is caused by increased production or reduced clearance of amyloid-β,
which results in the formation amyloid-β plaques and triggers a cascade of downstream …

Alzheimer's Disease (AD) is closely connected to aberrant lipid metabolism. However, how
early AD-like pathology synchronously influences brain and plasma lipidome in AD mice …

Abstract Background Shengmai San (SMS), a Chinese classic herbal formula, has been
widely used for the treatment of Qi-Yin deficiency syndrome in Asia. Modern …

Alzheimer's disease (AD) is the most common cause of dementia. Despite many years of
research, very limited treatment options are available. Here we aim to establish a well …

Alzheimer's disease (AD) is characterized by dysfunction in cognitive and noncognitive
domains with clinical diagnosis based on multiple neuropsychological tests. Here, we …

A large body of evidence has shown that cognitive deficits occur early, before amyloid
plaque deposition, suggesting that soluble amyloid-β protein (Aβ) contributes to the …